The scientist’s investigation covers issues in Internal medicine, Leukemia, Surgery, Gastroenterology and Cancer research. His research integrates issues of Immunology and Oncology in his study of Internal medicine. His research in Leukemia intersects with topics in Haematopoiesis, Myeloid leukemia and Myelodysplastic syndromes.
His Surgery study incorporates themes from Natural history and Disease. His Gastroenterology study combines topics from a wide range of disciplines, such as Salvage therapy and Cyclophosphamide. Miloslav Beran has researched Cancer research in several fields, including Chronic myelogenous leukemia, Extramedullary hematopoiesis, Philadelphia chromosome and ABL.
Miloslav Beran mainly focuses on Internal medicine, Gastroenterology, Leukemia, Surgery and Immunology. Internal medicine is frequently linked to Oncology in his study. Miloslav Beran has included themes like Toxicity, Phases of clinical research, Vincristine, Cyclophosphamide and Alpha interferon in his Gastroenterology study.
His work deals with themes such as Cancer research, Myeloid leukemia and Chronic myelomonocytic leukemia, Myelodysplastic syndromes, which intersect with Leukemia. His Myelodysplastic syndromes course of study focuses on Acute leukemia and Myelofibrosis. The various areas that he examines in his Immunology study include Angiogenesis, Disease and In vivo.
Miloslav Beran mostly deals with Internal medicine, Leukemia, Gastroenterology, Myeloid leukemia and Surgery. The Internal medicine study combines topics in areas such as Immunology and Oncology. The concepts of his Leukemia study are interwoven with issues in Cancer research, Chronic myelomonocytic leukemia, Myelodysplastic syndromes, Philadelphia chromosome and Myelofibrosis.
His Cancer research research integrates issues from Chronic myelogenous leukemia, Haematopoiesis and Apoptosis, Programmed cell death. His Gastroenterology research incorporates elements of Phases of clinical research, Adverse effect, Hazard ratio, Nausea and Bone marrow. While the research belongs to areas of Surgery, Miloslav Beran spends his time largely on the problem of Chronic lymphocytic leukemia, intersecting his research to questions surrounding Lumiliximab and Refractory Chronic Lymphocytic Leukemia.
Miloslav Beran mainly investigates Leukemia, Cancer research, Myeloid leukemia, Internal medicine and Chronic myelogenous leukemia. His Cancer research study integrates concerns from other disciplines, such as Cancer and Chronic myelomonocytic leukemia. His Myeloid leukemia research incorporates themes from Hematology and Single-nucleotide polymorphism.
His studies in Internal medicine integrate themes in fields like Gastroenterology, Surgery and Oncology. His Chronic myelogenous leukemia research includes themes of Imatinib, Imatinib mesylate and Philadelphia chromosome. His Philadelphia chromosome research is multidisciplinary, relying on both Myelodysplastic syndromes and Acute leukemia.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg.
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien.
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab.
Cancer Cell (2011)
Report of an international working group to standardize response criteria for myelodysplastic syndromes
B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto.
Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes.
Journal of Clinical Oncology (2000)
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero.
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes.
Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien.
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl.
Journal of Clinical Oncology (2005)
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
Hagop M. Kantarjian;Terry L. Smith;Susan O'Brien;Miloslav Beran.
Annals of Internal Medicine (1995)
If you think any of the details on this page are incorrect, let us know.